Ok, so technically this probably isn't a rumor. But, Fierce Biotech did report today on comments from the Wall Street analysts from Jeffries that BMS is doing so well that it would be a likely acquisition candidate. I'm not sure how much difference there is between them actually being in play and having influencial analysts group suggest 'they should be in play'.
In any event, on the heels of BMS' good fortune in getting Yervoy approved for the treatment of advanced melanoma, as well as making out with Eliquis (apixiban) for anti-clotting, the Fierce article names Pfizer as a Big Pharma company likely to be excited to acquire BMS. This is largely explained due to BMS expected improved positive cash flow from the above drugs as they penetrate the market, coupled with Pfizer's own cash flow dearth's resulting from drugs like Lipitor going generic.
And conveniently, Pfizer is partnered on Eliquis with BMS. A match made in pharma heaven eh? I don't know. I would have thought Pfizer learned a lesson on downsides of its last two mega-deals with Pharmacia and Wyeth. But what do I know?
Posted by Bruce Lehr Sep 19th 2011.
Comments